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Abstract
In 12 healthy male volunteers (27-53 yr), a placebo-con-
trolled randomized double blind cross-over trial was per-
formed to study the effect of the intravenous injection of
0.25, 0.5, 1, 2, 4, and 6 mg draflazine (a selective nucleoside
transport inhibitor) on hemodynamic and neurohumoral
parameters and ex vivo nucleoside transport inhibition. We
hypothesized that an intravenous draflazine dosage without
effect on hemodynamic and neurohumoral parameters
would still be able to augment the forearm vasodilator re-
sponse to intraarterially infused adenosine. Heart rate (elec-
trocardiography), systolic blood pressure (Dinamap 1846
SX; Critikon, Portanje Electronica BV, Utrecht, The Neth-
erlands) plasma norepinephrine and epinephrine increased
dose-dependently and could almost totally be abolished by
caffeine pretreatment indicating the involvement of adeno-
sine receptors. Draflazine did not affect forearm blood flow
(venous occlusion plethysmography). Intravenous injection
of 0.5 mg draflazine did not affect any of the measured
hemodynamic parameters but still induced a significant ex
vivo nucleoside-transport inhibition of31.5±4.1% (P < 0.05
vs placebo). In a subgroup of 10 subjects the brachial artery
was cannulated to infuse adenosine (0.15, 0.5, 1.5, 5, 15, and
50 ,ug/100 ml forearm per min) before and after intrave-
nous injection of 0.5 mg draflazine. Forearm blood flow
amounted 1.9+0.3 ml/100 ml forearm per min for placebo
and 1.8±0.2, 2.0±0.3, 3.8±0.9, 6.3±1.2, 11.3±2.2, and
19.3±3.9 ml/100 ml forearm per min for the six incremental
adenosine dosages, respectively. After the intravenous
draflazine infusion, these values were 1.6±0.2 ml/100 ml
forearm per min for placebo and 2.1±0.3, 3.3±0.6, 5.8±1.1,
6.9±1.4, 14.4±2.9, and 23.5±4.0 ml/100 ml forearm per
min, respectively (Friedman ANOVA: P < 0.05 before vs
after draflazine infusion). In conclusion, a 30-50% inhibi-
tion of adenosine transport significantly augments the fore-
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arm vasodilator response to adenosine without significant
systemic effects. These results suggest that draflazine is a
feasible tool to potentiate adenosine-mediated cardioprotec-
tion in man. (J. Clin. Invest. 1995. 95:658-668.) Key words:
nucleoside-transport inhibition * adenosine * autonomic ner-
vous system * forearm * human pharmacology
Introduction
Adenosine has important cardioprotective properties that are
mediated by stimulation of adenosine receptors, located on the
outer cell membrane. In animals, infarct size is reduced when
adenosine is infused either before ischemia or during the reper-
fusion period ( 1-3 ). Infusion of a selective adenosine receptor
antagonist increases infarct size, indicating a role for endoge-
nous adenosine as a cardioprotective autacoid (1). Adenosine
is a mediator of ischemic preconditioning (1, 2, 4), defined as
the increased tolerance of myocardium to a prolonged ischemic
insult achieved by an initial brief exposure to ischemia and
reperfusion (5). This phenomenon has originally been de-
scribed in animals (6). Also, in humans, a preconditioning
effect has been suggested (7, 8). At present, many potentially
cardioprotective effects of adenosine are known, like inhibition
of neutrophil activation with subsequent reduced free radical
formation, inhibition of thrombocyte aggregation, vasodilation,
presynaptic inhibition of norepinephrine release, opening of po-
tassium channels, and repletion of purine stores (9). From a
pharmacological point of view it seems of interest to develop
agents with a comparable local effect on the myocardium (10).
Within this concept, long-acting adenosine receptor agonists are
not useful because these drugs elicit pharmacological effects,
not only during ischemia but continuously, and not only in the
myocardium but in nearly all organ systems, resulting in a large
list of side effects (11, 12). Inhibition of the cellular uptake
of extracellular adenosine might be an alternative approach to
circumvent the disadvantages of intravenous adenosine infu-
sions (13). In animals, this concept has been evaluated by the
use of adenosine transport inhibitors like, for instance, dipyri-
damole. Dipyridamole appears to potentiate myocardial precon-
ditioning (14). In humans, dipyridamole is not a suitable tool
to potentiate the cardioprotective effect of endogenous adeno-
sine (15, 16) and this might be due to its nonspecific actions
like stimulation of prostacycline release and inhibition of phos-
phodiesterase (17, 18).
Recently, a new adenosine transport inhibitor, called
draflazine, has become available for human investigation. This
active (- )-enantiomer of the piperazine derivate R 75231 is a
highly specific adenosine transport inhibitor with a tighter bind-
ing to the transporter and looser binding to plasma proteins
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Table L Demographic Characteristics
n = 12 Mean (range)
Age (yr) 41 (27-53)
Weight (kg) 73.3 (62.3-88.5)
Length (cm) 179.5 (172.0-189.0)
Systolic blood pressure (mmHg)* 129 (112-140)
Diastolic blood pressure (mmHg)* 75 (62-88)
Heart rate (bpm)j 63 (48-72)
* Auscultatory measurements with sphygmomanometer after 5 min of
supine rest (systolic blood pressure: Korotkoff I; diastolic blood pres-
sure: Korotkoff V). I Measured by pulse frequency counting after 5
min of supine rest.
when compared with dipyridamole (19). In rabbits, R 75231
has shown to prevent death from catecholamine-induced cardiac
toxicity (20) and to improve functional recovery after cardiac
ischemia (21). In pigs, R 75231 reduces ischemia-induced ar-
rhythmias (22). The present study explores the hemodynamic
53. Smits, P., T. Thien, and A. van't Laar. 1985. Circulatory effects of coffee
port inhibition in man. Our results convincingly show that inhi-
bition of adenosine transport by 70% or more increases blood
pressure, heart rate, and plasma catecholamines. In contrast,
low grade inhibition to 30-50% does not evoke any systemic
hemodynamic changes but still potentiates the vasodilator ef-
fects of adenosine at a site of increased supply. These observa-
tions should be taken into account when draflazine is used as
an "on demand" drug to potentiate the beneficial effects of
adenosine as released during ischemia.
Methods
Subjects. After approval of the local ethics committee, 12 normotensive
nonsmoking healthy Caucasian male volunteers signed written informed
consent before participation in the study. Demographic data are shown
in Table I. They had no history of hypertension, diabetes mellitus, or
drug allergy, and did not use concomitant medication. In all volunteers
a physical examination, routine laboratory investigation, and a 12-elec-
trocardiography lead were performed to exclude cardiovascular, pulmo-
nary, renal, liver, or neurologic disease.
Critical dose fnding (part 1). In this study, the circulatory effects
of six dosages of draflazine were investigated (0.25, 0.5, 1, 2, 4, and
6 mg).
First, in a double-blind randomized cross-over design, the hemody-
namic and neurohumoral effects of placebo and 1, 2 or 4 mg draflazine
were studied during four sessions per volunteer, that were separated by
at least 1 wk. At least 1 wk thereafter, and after proven tolerance to the
previous dosages, the effect of 6 mg draflazine was studied in a single-
blind fashion. This 6-mg dose was not included in the randomized
double-blind approach for safety reasons, on request of the ethics com-
mittee. After the randomization code had been broken, data analysis
showed that all dosages, including the lowest, induced a statistically
significant increase in heart rate. Therefore, the trial was prolonged
with two visits per volunteer, separated by at least I wk, to study the
hemodynamic effects of 0.25 and 0.5 mg draflazine in a double-blind
randomized fashion.
Each experiment was performed in the morning after a 24-h absti-
nence from caffeinated products and an overnight fast of at least 10 h.
Both arms were intravenously cannulated to infuse drug (left arm) and
to collect blood (right arm). After an equilibration period of at least 45
min in supine position, placebo or drug was intravenously infused for
15 min using an automatic syringe infusion pump (type STC-52 1;
Terumo Corp., Tokyo, Japan). From 5 min before until 60 min after
the start of the infusion, heart rate was measured by standard electrocar-
diography and continuously recorded on tape (Oxford 9000 with ADgi
preamplifier, band pass 0.05-40Hz (-3dB); Oxford Medical, Gorin-
chem, the Netherlands). Starting immediately before and continuing
until 60 min after the start of the drug infusion, BP (Dinamap 1846
SX; Critikon, Portanje Electronica BV, Utrecht, The Netherlands) and
forearm blood flow (FBF)' were measured at the left arm at 5- and 15-
min intervals, respectively. FBF was registered by electrocardiography-
triggered venous occlusion plethysmography using mercury-in-silastic
strain gauges (EC4; D. E. Hokanson, Inc., Washington, DC). The upper
arm collecting cuff was inflated using a rapid cuff inflator (E-20; D. E.
Hokanson, Inc.). At least 1 min before the FBF measurements, the
circulation of the left hand was occluded by inflation of a wrist cuff to
200 mmHg. FBF was recorded three times per min during 3 min.
Before the start of each intravenous injection, blood was collected
for the measurement of the plasma caffeine concentration.
Immediately before and 15, 30, and 60 min after the start of the
intravenous infusion of placebo, 1, 2, 4 or 6 mg draflazine, blood was
collected to determine plasma epinephrine (EPI), NE, and adenosine
concentration and to measure ex vivo adenosine transport inhibition
(see Analytical Methods). Additionally, 15, 30, and 60 min after the
start of the infusion, blood was collected to measure whole blood
draflazine concentrations (see Analytical Methods). After administra-
tion of 0.25 and 0.5 mg draflazine, only adenosine transport inhibition
and draflazine concentrations were determined.
Effect of the adenosine receptor antagonist caffeine on hemody-
namic and neurohumoral responses to draflazine (part 2). To investi-
gate the contribution of adenosine-receptor stimulation in the hemody-
namic and neurohumoral responses to draflazine, in a subgroup of 10
subjects, informed consent was obtained to repeat the intravenous injec-
tion of 4 mg draflazine during adenosine-receptor blockade with caf-
feine, an adenosine-receptor antagonist in humans ( 11). 40 min before
the start of the draflazine injection, a 10-min intravenous caffeine infu-
sion was started (4 mg/kg), as described previously (23). Blood pres-
sure, heart rate, catecholamines, plasma caffeine concentration, and
adenosine transport inhibition were measured immediately before the
start of the caffeine infusion, immediately before the start of the draflaz-
ine infusion, and at regular time intervals thereafter as mentioned above.
Draflazine-induced changes in hemodynamic and neurohumoral parame-
ters were compared with those as obtained in part 1 of this study.
Effect of 0.5 mg draflazine on the forearm vasodilator response to
adenosine (part 3). In 10 of the 12 subjects, informed consent was
obtained for a third study part to investigate the effect of 0.5 mg drafla-
zine (critical dose) on the forearm vasodilator response to intraarterially
infused adenosine. This dose was chosen because it was the highest
dose of draflazine which did not affect baseline hemodynamic or neuro-
humoral parameters. Before the start of the study, the subjects were
asked to abstain from caffeine-containing products for at least 24 h. All
tests were performed in the supine position after an overnight fast,
starting at 8:00 a.m. After administration of a 2% local anesthesia (Xylo-
caine; Astea Pharmaceutical Products Inc., Worcester, MA), the left
brachial artery was cannulated with a 20-gauge catheter (Angiocath;
Deseret Medical, Inc., Becton Dickinson and Co., Sandy, UT) for both
intraarterial adenosine infusion (automatic syringe infusion pump, [type
STC-521; Terumo Corp.]) and blood pressure recording (Hewlett Pack-
ard GmbH, Boblingen, Germany). Forearm blood flow was registered
simultaneously on both forearms by electrocardiography triggered ve-
nous occlusion plethysmography as stated above.
The experiment started with the measurement of baseline FBF during
placebo infusion (NaCl, 0.9%). The effect of six increasing dosages of
adenosine (0.15, 0.5, 1.5, 5, 15, and 50 [lg/l00 ml forearm per min)
were compared with placebo (NaCl 0.9%). Prolonged occlusion of the
1. Abbreviations used in this paper: EPI, epinephrine; FBF, forearm
blood flow.
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hand circulation can cause discomfort with subsequent effects on blood
pressure and heart rate. Therefore, a 5-min rest was allowed between
the placebo infusion and the first adenosine infusion and between the
third and fourth adenosine infusion. 45 min after the last adenosine
infusion, the intraarterial placebo infusion was repeated and followed
by a 15-min intravenous injection of 0.5 mg draflazine in the right arm.
Subsequently, the vasodilator response to adenosine was studied again.
Additionally, the ex vivo adenosine transport inhibition was measured
at regular time intervals. During all procedures, total infusion was ad-
justed to forearm volume as measured by water displacement and kept
at a constant rate of 100 IL/ 100 ml forearm per min. Placebo and each
adenosine dosage were infused for 4 min.
In a separate group of six healthy, nonsmoking male volunteers the
same protocol was performed except for the intravenous infusion of
draflazine (time control study).
Analytical methods. Samples for determination of plasma caffeine
concentration were analyzed with a reversed-phase HPLC method (limit
of detection: 0.2 ,ug/ml) (24).
Plasma levels of EPI and NE were determined simultaneously by
an HPLC method with fluorimetric detection, in which catecholamines
are concentrated from plasma by liquid-liquid extraction and derivated
with the selective fluorescent agent 1,2-diphenylethylenediamine before
chromatography as has been described in more detail elsewhere (25).
The interassay coefficients of variation in our laboratory are 7.2% and
8.5% at a mean concentration of 0.15 and 1.02 nmol/liter for EPI and
NE, respectively (n = 52).
To measure plasma adenosine concentration, 2 ml blood was col-
lected and directly mixed during collection with 2 ml blocker solution
using a specially designed device. The blocker solution contained the
adenosine deaminase inhibitor erythro-9(2-hydroxy-3-nonyl)-adeno-
sine (10 uM), the adenosine transport inhibitor dipyridamole (20 OM)
and the thrombocyte aggregation inhibitor indomethacine (2 mg/liter).
Immediately after blood collection the blood/blocker mixture was cen-
trifuged (model 3200; Eppendorf North America, Inc., Madison, WI)
at 3,000 rpm for 2 min and the plasma was deproteinated with perchloric
acid as described before (26). The extract was kept frozen at -20'C
until the adenosine concentration was determined in duplicate by re-
versed-phase, high performance liquid chromatography using a nonlin-
ear gradient.
In five subjects 12 ml blood/blocker mixture was collected before
administration of 0.25 or 0.5 mg draflazine and divided into six equal
portions. Adenosine standards were added to five separate blocker/mix-
ture portions. The six portions were handled as stated above. The ex-
pected increases in adenosine concentration, as compared with the
control blood/blocker mixture were 0.029, 0.052, 0.110, 0.210, and
0.405 1LM. The averaged recoveries were 115.9±31.3, 144.7±24.6,
109.6± 11.6, 114.5± 15.6, and 126.7± 12.2% for the five increasing stan-
dards, respectively. The detected increase in plasma adenosine concen-
tration tended to be overestimated, although this was not statistically
significant (P = 0.3, n = 5; Friedman ANOVA). In each individual a
maximal correlation of 1.0 was observed between expected and mea-
sured adenosine concentration. The individual regression coefficients
ranged from 1.0 to 1.7 (mean±SE: 1.3±0.1). The intraassay variability,
calculated as the coefficient of variation in the duplicate-determinations
at baseline (five duplicate determinations in 11 subjects) was
16.2±2.2%. The short-term intraindividual variability in measured ade-
nosine concentration, calculated as the coefficient of variation of the
four measurements during placebo infusion, was 20.7±7.2%.
Ex vivo adenosine transport inhibition was measured by standardized
incubation of erythrocytes with adenosine. 4 ml blood was drawn into
a vial containing 1 ml acid, citrate, and dextrose (85 mM trisodium
citrate, 65 mM citric acid and 20 g/liter glucose) and further handled
as described before (22). The percent inhibition of adenosine transport
(ATI %) was calculated as:
ATI% = (A, - Ao) x 100/(1 - AO)
in which Ao represents the adenosine concentration as proportion of the
sum of the concentration of adenosine, inosine, and hypoxanthine as
determined in the sample collected just before the drug infusion and Ax
represents this proportion as determined in the sample collected after
the start of the drug infusion.
Whole-blood draflazine concentration was detected by HPLC (limit
of detection: 5.0 ng/ml).
Drugs and solutions. Sterile solutions of draflazine or placebo in a
formulation with 5% hydroxypropyl-/-cyclodextrine (Janssen Pharma-
ceutica Inc., Beerse, Belgium), were prepared with NaCl 0.9% on the
morning of the study day by a specially trained research nurse, who
was not otherwise involved in the practical performance of the trial.
The randomization code was broken at the end of the trial, after all
calculations on forearm blood flow were performed. Sterile solutions of
caffeine (OPG Pharma, Utrecht, The Netherlands) and adenosine
(Sigma Chemical Co., St. Louis, MO) were freshly prepared by the
investigator with NaCl 0.9% as solvent.
Statistics. Heart rate, as derived from continuously recorded R-R
intervals, was averaged for each consecutive 5-min interval. The 5-min
interval just before draflazine or placebo infusion was taken as baseline.
For the other hemodynamic and neurohumoral parameters, the values
obtained just before the intravenous infusion were taken as baseline.
For each experiment, the effect of drug administration was calculated
at each time point as change from baseline. Since hemodynamic parame-
ters appeared to be normally distributed (P > 0.1; Shapiro-Wilk test
for normality), differences in changes from baseline between placebo
and draflazine administration were assessed by an ANOVA for repeated
measurements with the drug dosage, and time as within-subject factors.
The neurohumoral parameters were not normally distributed (P < 0.1;
Shapiro-Wilk test for normality). If an overall analysis by Friedman
two-way nonparametric ANOVA showed significant differences in re-
sponses (P < 0.05, by means of Chi-square approximation), the paired
Wilcoxon signed rank test was used to detect which draflazine dosages
were different from placebo. During the intraarterial study (part 3),
mean arterial pressure was measured continuously during each recording
of FBF and averaged per FBF registration. Forearm vascular resistance
was calculated from simultaneously measured mean arterial pressure
and FBF and expressed as arbitrary units. Additionally, the ratio of
each simultaneously measured FBF (FBF infused/FBF control arm)
was calculated. FBFs, the calculated flow ratios and forearm vascular
resistances obtained during each 4 min of placebo infusion or during
the last 2 min of each drug infusion, were averaged to one value.
Adenosine-induced effects were expressed both as absolute and percent
change from preceding placebo infusion. The overall effect of draflazine
on the adenosine dose response curve was analyzed by Friedman two-
way nonparametric ANOVA. All results are expressed as mean±SE
unless indicated otherwise; P < 0.05 (two sided) was considered to
indicate statistical significance.
Results
Plasma caffeine levels were determined to check the compliance
with respect to the caffeine abstinence. For part 1 of this study,
in four subjects, the plasma caffeine concentration was below
the limit of detection for all visits. In six subjects the plasma
caffeine concentration remained below 1 mg/liter. In one sub-
ject caffeine was only detectable before the infusion of 1 mg
draflazine (1.4 mg/liter) and in another subject, caffeine was
detectable during five of the seven visits ranging from 0.5 to
1.6 mg/liter. For part 2 of this study, plasma caffeine was
detectable in two subjects being 0.2 mg/liter for both. In part
3 of this study, plasma caffeine was detectable in three subjects
being 0.8, 0.3, and 0.25 mg/liter. These plasma caffeine concen-
trations indicate a good compliance with regard to the caffeine
abstinence. In the second part of the study, caffeine was admin-
istered in a dose of 4 mg/kg. 30 min after the caffeine infusion
and immediately before the start of the draflazine infusion,
plasma caffeine concentration was on average 5.7±0.2 mg/liter.
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Table II. Baseline Characteristics Before Each Drug Infusion (Mean ± SE)
Draflazine dosage
n = 12 placebo 0.25 mg 0.5 mg 1 mg 2 mg 4 mg 6 mg
Systolic BP (mmHg) 108.2±3.0 108.5±2.5 108.5±2.9 107.5±3.0 105.4±2.8 107.9±2.7 104.8±3.7
Diastolic BP (mmHg) 68.6±1.6 69.3±1.6 69.5±1.5 66.4±1.4 66.1±1.9 69.0±1.9 66.1±2.2
MAP (mmHg) 83.4±2.0 82.9±1.8 83.7±1.8 81.3±1.5 80.4±2.3 83.2±2.2 80.3±2.8
Heart rate (bpm) 60.6±2.0 61.7±1.5 60.8±1.9 60.6±2.3 61.5±1.9 59.8±1.8 61.4±2.5
FBF (mli100 ml per min) 1.8±0.3 2.1±0.5 1.6±0.3 1.4±0.2 1.5±0.2 1.3±0.2 1.8±0.2
NE (nmoliter) 1.2±0.1 1.1±0.1 1.2±0.1 1.3±0.2 1.3±0.2
EPI (nmol/liter) 0.10±0.02 0.11±0.02 0.09±0.01 0.09±0.01 0.08±0.02
Adenosine (,umol/liter) 0.17±0.07 0.22±0.08 0.39±0.13 0.39±0.18 0.35±0.17
Subjective side effects to draflazine. Up to 2 mg draflazine,
no subjective side effects occurred. In one subject, the 4-mg
dose induced a slight headache and a feeling of dyspnea. Previ-
ous intravenous injection of caffeine completely prevented these
complaints. In 8 of the 12 subjects, the 6-mg dose induced
temporary subjective side effects ranging from a feeling of ex-
citement (n = 4) and/or headache (n = 4) to nausea (n = 3)
that was accompanied by vomiting and chest pain (without
electrocardiographic changes) in one subject. These subjective
side effects might have affected the recordings, resulting in less
accurate measurements during and after the administration of 6
mg draflazine as compared with the lower dosages.
Critical dose finding. Table II shows mean baseline values
for all measured parameters. Overall, no statistically significant
differences in baseline values were observed. Fig. 1 shows the
time course of changes in blood pressure and heart rate during
the varying draflazine infusions as compared with placebo. Up
to 0.5 mg, draflazine did not induce a significant increase in
heart rate. Heart rate increased by maximally 2.0±1.1 for pla-
cebo and 1.8±0.5, 3.3±0.8, 6.1±0.7, 15.2±2.3, 29.2±2.6, and
32.5±2.8 bpm for 0.25, 0.5, 1, 2,4, and 6 mg draflazine, respec-
tively (P < 0.01 vs placebo for 1, 2, 4 and 6 mg draflazine, n
= 12). Up to 1 mg draflazine, systolic blood pressure was not
significantly affected. At higher dosages, the maximal mean
systolic blood pressure response increased dose-dependently by
9.1±1.4, 12.5+3.2, and 18.0±3.1 mmHg for 2, 4, and 6 mg
draflazine, respectively (P < 0.05 vs placebo, n = 12). The
most important increase in systolic blood pressure occurred
during the first 15 min after starting the draflazine infusion.
Neither diastolic blood pressure, mean arterial pressure nor fore-
arm blood flow were significantly affected by draflazine. When
forearm vascular tone was expressed as vascular resistance (ra-
tio of mean arterial pressure and forearm blood flow), still no
effect of draflazine on forearm vasculature could be observed.
The effect of draflazine on plasma NE and EPI concentration
are shown in Fig. 2. Starting with 2 mg, draflazine induced a
dose-dependent increase in plasma NE concentration that
reached a maximum at 30 min after starting the infusion. At
this time point, the increase in NE concentration was 0.7±0.1,
1.0+0.2, and 1.7±0.3 nmol/liter for 2, 4, and 6 mg draflazine,
respectively (P < 0.05 vs placebo, n = 12).
After infusion of 1 mg draflazine, the EPI concentration was
not significantly affected. Infusion of 2 mg draflazine induced
a small increase in EPI concentration of 0.02±0.01 nmol/liter
at 15 min after starting the draflazine infusion (P < 0.05 vs
placebo, n = 12). Up to 60 min after the start of the infusion
of 4 or 6 mg draflazine, the EPI concentration continuously
increased maximally by 0.15±0.03 and 0.31±0.06 nmol/liter,
respectively (P < 0.05 vs placebo, n = 12).
The course of ex vivo adenosine transport inhibition is
shown in Fig. 3. 15 min after the start of each draflazine infu-
sion, maximal adenosine transport inhibition was achieved be-
ing 0.2±0.7 for placebo and 10.2±2.3, 31.5±4.1, 70.4±1.5,
80.6+0.9, 89.6± 1.1, and 92.6±0.6% for 0.25, 0.5, 1, 2, 4, and
6 mg draflazine, respectively (P < 0.05 for each dosage vs
placebo). 60 min after starting the infusion, there still remained
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Figure 1. Effect of draflazine on systolic blood pressure (SBP), diastolic
blood pressure (DBP), and heart rate. *, Significant difference with
placebo (n = 12).
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Figure 2. Effect of draflazine on plasma catecholamines. *, Significant
difference with placebo (n = 12).
a significant adenosine transport inhibition being -0.9±0.8 for
placebo and 6.0±0.8, 14.2±1.1, 22.3±3.0, 42.5±1.7, 59.8±1.9,
and 68.3±2.0% for the six draflazine doses, respectively (P
< 0.05 for each dosage vs placebo). For each subject, the rela-
tion between drug concentration and ex vivo adenosine transport
inhibition was assessed by computer assisted curve fitting using
the Hill equation (Fig. 4). For this analysis, minimal and maxi-
mal ex vivo adenosine transport inhibition was set constant at
0 and 100% respectively. The best fitting drug concentration
with 50% ex vivo adenosine transport inhibition and Hill coef-
ficient were 74.1±2.4 ng/ml (range: 55.5-88.1 ng/ml; n = 12)
and 3.2±0.1 (range: 2.5-4.0; n = 12), respectively. According
to this model, 95±1% of the variation in ex vivo nucleoside
transport inhibition could on average be explained by the blood
draflazine concentration.
For each subject, the relation between draflazine-induced
heart rate response (difference with response after placebo infu-
sion) and ex vivo adenosine transport inhibition was assessed
at 15, 30, and 60 min after starting the draflazine infusion (Fig.
5). Up to 50% inhibition of adenosine transport, heart rate
was unaffected. An equation in the form ofY = AX3 appeared to
describe the relation between heart rate response and adenosine
transport inhibition most accurately. Nonlinear regression anal-
ysis revealed a mean value for A of (3.0±0.3) *10',
(6.1±0.4) *10-5, and (7.7±0.8) * 10-5 at 15, 30 and 60 min,
respectively. With this model, 77±2, 90±2, and 81±3% of the
intraindividual variation in heart rate response could be ex-
plained by ex vivo nucleoside transport inhibition at 15, 30 and
60 min after starting the draflazine infusion, respectively.
.I
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I*-# 6 mg
0 15 30 45 60
Time after start of infusion (min)
Figure 3. Effect of draflazine on ex vivo nucleoside transport inhibition
(top) and plasma-adenosine concentration (bottom), respectively. *,
Curves that were significantly different from placebo at all time points
(n = 12).
Apart from ex vivo adenosine transport inhibition, Fig. 3
shows the effect of draflazine on plasma adenosine concentra-
tion. Draflazine did not induce significant changes in plasma
adenosine concentration (P > 0.5, n = 11).
Effect of the adenosine receptor antagonist caffeine on he-
modynamic and neurohumoral responses to draflazine. Baseline
values after caffeine infusion were significantly increased for
systolic, diastolic, and mean arterial pressure and plasma epi-
nephrine concentration and reduced for heart rate when com-
pared with baseline values without caffeine pretreatment (Table
Ill). Fig. 6 shows the effect of intravenous caffeine infusion (4
mg/kg) on the course of systolic blood pressure, heart rate,
epinephrine, and norepinephrine after draflazine infusion. Caf-
feine pretreatment reduced the heart rate response to the 4-mg
dose of draflazine from 29.3±3.8 bpm (32.6±3.0%) to 8.8± 1.0
(13.9±1.4%) (P < 0.01 vs placebo and vs draflazine without
caffeine pretreatment). The systolic blood pressure response to
draflazine was reduced from 11.7±3.7 mmHg (10.7±3.3%)
without caffeine pretreatment to 4.9±1.7 mmHg (4.3±1.5%)
after caffeine pretreatment (P = NS versus placebo, P < 0.05
vs draflazine without caffeine pretreatment).
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Ex vivo adenosine transport inhibition in relation
to drug concentration
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Figure 4. Relation between percent inhibition in adenosine transport
and whole-blood draflazine concentration. This relation was evaluated
for each subject using the Hill equation. For each individual, the best
fitting Hill coefficient and IC50 (draflazine concentration that exhibits
50% of the maximal effect) were calculated by computer-assisted curve
fitting (n = 12).
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Caffeine pretreatment reduced the increase in NE concentra-
tion after the 4-mg dose of draflazine from 1. 1±0.23 nmol/liter
(105.6±22.6%) to 0.2±0.1 nmol/liter (23.7±4.1%) (P = NS
vs placebo and P < 0.05 vs draflazine infusion without caffeine
pretreatment). The increase in plasma epinephrine concen-
tration after 4 mg draflazine was reduced from 0.14+0.04
nmol/liter (177.0+42.2%) without caffeine pretreatment to
0.09±0.02 nmol/liter (73.1 + 12.9%) after caffeine pretreatment
(P = NS vs placebo and P < 0.05 vs draflazine without caffeine
pretreatment).
Draflazine induced a significant inhibition of nucleoside
transport of 89.3±1.1, 71.5±1.3, and 59.4±1.8% at 15, 30, and
60 min after the start of the draflazine infusion, respectively,
and these figures did not significantly differ from adenosine
transport inhibition as observed after infusion of 4 mg draflazine
without caffeine pretreatment.
Effect of0.5 mg draflazine onforearm vasodilator response
to adenosine. Intraarterial infusion of adenosine increased fore-
arm blood flow dose dependently. The baseline forearm blood
flow was 1.9±0.3 and 1.6±0.2 ml/ 100 ml forearm per min in
the infused and control arm, respectively. During the subsequent
six incremental adenosine infusions, the forearm blood flow
in the infused arm amounted to 1.8+0.2, 2.0±0.3, 3.8±0.9,
6.3±1.2, 11.3+2.2, and 19.3+3.9 ml/100 ml per min, respec-
tively. In the control arm, forearm blood flow remained un-
changed. Draflazine did not affect forearm blood flow: in the
infused arm, forearm blood flow was 1.8±0.2 and 1.6±0.2 ml/
100 ml per min immediately before and after the draflazine
infusion, respectively (control arm: 1.3+0.1 and 1.2+0.2 ml/
100 ml per min). However, draflazine significantly augmented
the adenosine-induced changes in forearm blood flow. After the
draflazine infusion, the forearm blood flow in the infused arm
amounted 2.1±0.3, 3.3±0.6, 5.8±1.1, 6.9±1.4, 14.4±2.9, and
23.5+±4.0 ml/ 100 ml forearm per min during the six incremental
adenosine infusions, respectively (P < 0.05 vs adenosine infu-
sions before draflazine treatment). In the control arm, forearm
blood flow remained unchanged. Fig. 7 shows the effect of
60r
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Y=AX3
A=(7.75±0.80)*10-5
r2=0.81+0.03
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Figure 5. Relation between heart rate response and adenosine transport
inhibition. At each time point and for each individual, this relation was
evaluated by computer assisted curve fitting. An equation in the form
of Y = AX3 appeared to result in the best fitting curves. The individual
values for A and r2 (squared correlation coefficient) were averaged and
are depicted in the figure as mean+SE (n = 12).
draflazine on the forearm vasodilator response to adenosine,
expressed as percent change in forearm vascular resistance. The
same effect of draflazine was observed when results were ex-
pressed as forearm vascular resistance or flow ratio both ex-
pressed as absolute as well as percent changes from baseline.
The time control study did not reveal a significant change in
adenosine-induced forearm vasodilation, excluding significant
carry-over effects (see lower panel of Fig. 7). Heart rate was
57.5±1.7 and 58.4±1.4 beats per minute (bpm) immediately
before and after draflazine infusion, respectively (P > 0.2),
confirming that the used draflazine dosage did not induce sys-
temic effects.
Ex vivo nucleoside transport inhibition was 47.9±3.2,
21.6±1.6, and 15.0±1.5% at the end of the draflazine infusion,
and at the end of the third and sixth intraarterial adenosine dose,
respectively.
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Table III. Effect of Caffeine on Baseline Parameters
Before placebo Before 4 mg draflazine
Without caffeine Without caffeine With caffeine
pretreatment pretreatment pretreatment
n = 10
Systolic BP (mmHg) 108.8±3.4 108.5±3.1 113.0±2.1*t
Diastolic BP (mmHg) 68.9±1.9 68.9±2.3 73.1±1.6*'
MAP (mmHg) 83.8±2.3 83.5±2.5 87.3±1.7'
Heart rate (bpm) 59.0±2.2 58.4±1.4 53.9±1.4*t
NE (nmol/liter) 1.2±0.1 1.3±0.2 1.0±0.l*t
EPI (nmo~liter) 0.11±0.02 0.09±0.02 0.14±0.02'
* and * Significantly different from baseline values before placebo and
4 mg (without caffeine treatment), respectively, § Friedman two-way
ANOVA: P = 0.08; Wilcoxon matched-pairs, signed-ranks test: P
= 0.03 vs 4 mg draflazine (without caffeine pretreatment).
Discussion
This study was aimed at finding a draflazine dosage without
unwanted hemodynamic and neurohumoral effects that still po-
tentiates the beneficial effects of adenosine at sites of increased
formation. Therefore, a dose-response trial was performed that
revealed a dose-dependent increase in systolic blood pressure,
heart rate, and plasma catecholamines in subjects that refrained
from caffeine-containing products for at least 24 h. Preceding
caffeine infusion abolished all draflazine-mediated effects, con-
firming that they were mediated by adenosine receptor stimula-
tion. Heart rate appeared to be the most sensitive parameter
15
10
5
0
ASBP t%)
A A I
Ak I..ft ,, -A*i
to detect unwanted effects. An intravenous dosage of 0.5 mg
draflazine did not affect heart rate, but still induced an ex vivo
transport inhibition by - 30%. To test the hypothesis that this
critical dose is able to potentiate the vasodilatory effects of
adenosine in humans at sites of increased formation, the per-
fused forearm technique was used as a model of local adenosine
formation. Intravenous infusion of 0.5 mg draflazine appeared
to augment the forearm vasodilator response to adenosine three-
fold, suggesting that a low grade adenosine transport inhibition
is a feasible approach to exploit the beneficial effects of endoge-
nous adenosine in humans.
Hemodynamic and neurohumoral effects ofdraflazine. With
regard to the cardiovascular system, adenosine can induce direct
and indirect effects. The direct effects of adenosine include
negative inotropic, chronotropic, and dromotropic effects (27),
relaxation of vascular smooth muscle (except in the pulmonary
and renal vascular bed where vasoconstriction is observed) (28,
29), pre- and postsynaptic inhibition of adrenergic neurotrans-
mission (30, 31), reduction of renal renin release (32-34),
stimulation of vascular angiotensin II production (35) and in-
hibitory effects on cardiovascular centers in the brainstem, ex-
cept for the nucleus tractus solitarii that is excitated by adeno-
sine, resulting in an increased sensitivity of the baroreflex (36).
These effects are thought to be involved in the hypotensive
response to intravenously administered adenosine as observed
in animals and anesthetized humans. The indirect effects are
mediated by adenosine-induced stimulation of afferent nerves,
including renal (37, 38) and myocardial afferent nerves (39a),
carotid and aortic chemoreceptors (12, 39), and forearm (mus-
cle) afferent nerves (40). Stimulation of these afferents results
in activation of the sympathetic nervous system and respiratory
system (11, 41) and a subsequent increase in systolic blood
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Figure 6. Effect of caffeine pre-
.*.^treatment (4 mg/kg) on the
. _ _ _- - draflazine (4 mg) -induced in-
creases in systolic blood pressure
(SBP), heart rate, NE, and EPI.
*And ', significant differences
0 15 30 45 60 with placebo or draflazine after
Time after start of infusion (min) caffeine pretreatment, respec-tively (n = 10).
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_Figure 7. Adenosine-induced
forearm vasodilation expressed as
FVR (quotient of MIAP and FBF)
in infused and control arm. (Top)
effect of intravenous drafiazine
treatment (n = 10); - before
draflazine infusion; - - - after
draflazine infusion. (Bottom)
Time control study (n = 6);
- first dose response curve;
- - - second dose response curve.
P values indicate level of signifi-
cance for the difference between
both curves (n = 10).
pressure, and plasma renin activity (11, 12, 41-45). The in-
crease in heart rate is probably mediated by concomitant deacti-
vation of the parasympathetic nervous system since it can be
antagonized by atropine, but not by propranolol (46). These
indirect effects of intravenous adenosine infusion are dependent
on an intact autonomic reflex arc (12), which probably explains
why these effects are blunted in anesthetized humans and ani-
mals (47-49). The increase in systolic blood pressure is not
always observed during intravenous infusion of adenosine in
healthy volunteers (46, 50-52). This apparent discrepancy in
the literature can be explained by differences in caffeine absti-
nence which is always relatively short or totally absent in the
studies in which no increase in systolic blood pressure is ob-
served. After ingestion of two cups of regular coffee, plasma
caffeine concentrations are in the range of 4-5 mg/liter (53),
which is sufficiently high to antagonize the hemodynamic ef-
fects of intravenous adenosine infusion (11I). The plasma half-
life time of caffeine after ingestion of two cups of coffee ranges
from 2 to 8.5 h (53). Therefore, a 24-h period of caffeine
abstinence is important to prevent underestimation of adeno-
sine-induced hemodynamic and neurohumoral effects. An in-
crease in systolic blood pressure, heart rate, and plasma cate-
cholamines has also been observed in resting humans after ad-
ministration of the adenosine transport inhibitor dipyridamole
(23, 54) and could be inhibited by previous administration of
caffeine or theophylline (23, 55), suggesting that adenosine is
formed under baseline conditions. In addition to the variable
oral bioavailability of dipyridamole and its lack of specificity
(17, 18, 56, 57), these excitatory effects of dipyridamole may
be an explanation for its disappointing effect on cardiovascular
mortality in large trials (15, 16).
It was expected from the previous experiments with adeno-
sine and dipyridamole in healthy, conscious human volunteers,
that draflazine, too, could induce hemodynamic and neurohu-
moral effects that would be unfavorable in patients with isch-
emic heart disease. The present study indeed confirms most
of these observations and substantiates them by showing their
dependency on the degree of ex vivo adenosine transport inhibi-
tion. Moreover, we observed an increase in both EPI and NE
during high degrees of selective adenosine transport inhibition,
supporting the involvement of the sympathetic nervous system
in this excitatory response. The increase in systolic blood pres-
sure without a change in mean arterial pressure excludes baro-
reflex activation as a possible mechanism for the increased
plasma catecholamine concentrations. Activation of sympa-
thetic tone by draflazine-induced myocardial ischemia is very
unlikely because the study was performed in healthy subjects
without a history of cardiovascular disease. Additionally, con-
tinuous electrocardiography did not demonstrate myocardial
ischemia. However, a yet unknown direct effect of draflazine
on the kinetics of catecholamines cannot be excluded.
Effect of caffeine pretreatment on draflazine-induced hemo-
dynamic and neurohumoral responses. Caffeine pretreatment
almost completely abolished the effect of draflazine on systolic
blood pressure, heart rate, and plasma catecholamines. This
antagonism occurred at a plasma caffeine concentration of 5.7
mg/liter, a concentration that can occur after drinking one cup
of coffee (53). The property of caffeine as a competitive adeno-
sine receptor antagonist has been well documented in human
in vivo studies (1 1, 29, 58, 59). Therefore, the observed antago-
nism of draflazine-induced hemodynamic and neurohumoral re-
sponses by caffeine indicates the involvement of adenosine re-
ceptors in draflazine-induced effects.
30 min after caffeine pretreatment, baseline values of sys-
tolic, diastolic, mean arterial pressure, and plasma epinephrine
concentration were increased and baseline heart rate was re-
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duced. These findings are in agreement with previous reports
about the effect of caffeine (24). The changes in baseline blood
pressure, heart rate, and epinephrine that were associated with
caffeine pretreatment could have interfered with the subsequent
effects of draflazine infusion. However, the magnitude of the
increased baseline levels after caffeine are almost negligible
when compared with the effects of draflazine.
Draflazine-induced adenosine transport inhibition was not
significantly affected by caffeine pretreatment. Therefore, the
effect of caffeine on draflazine-induced hemodynamic and neu-
rohumoral responses cannot be explained by differences in the
degree of adenosine transport inhibition.
In theory, inhibition of 5 '-nucleotidase by caffeine could
have diminished the formation of extracellular adenosine (60).
However, inhibition of the ecto-5'-nucleotidase, as obtained
from rat brain, occurs at a caffeine concentration of 1.0 mM
which is considerably higher than the plasma caffeine concen-
tration of 5.7 mg/liter (equivalent to 0.03 mM) as observed in
this study. Therefore, caffeine-induced inhibition of extracellu-
lar adenosine formation is not likely in the present study.
Draflazine and plasma adenosine concentration. Draflazine
failed to increase plasma adenosine concentrations. Two possi-
ble explanations will be discussed: (a) the lack of an observed
plasma adenosine increase is due to a measurement error and
(b) adenosine concentrations are increased in the interstitium
only.
(a) The precision of the adenosine determinations in the
present study does not essentially differ from that reported by
others (61). As stated in Methods, the recovery of adenosine
added to plasma was high and appeared to be linear within the
physiological range. Therefore, a systematic measurement error
is unlikely. Both German et al. and Sollevi et al. observed a
doubling in plasma adenosine concentration after administration
of the adenosine transport inhibitor dipyridamole (55, 62).
However, in both studies, adenosine formation, uptake, and
breakdown after blood sampling were not optimally antago-
nized. German et al. did not use a blocker solution (62, 63),
while Sollevi et al. used a blocker solution that was mixed
with blood immediately after, instead of during, blood sampling
(55). Therefore, in these studies, baseline plasma adenosine
concentrations may have been underestimated. The adminis-
tered dipyridamole may have affected adenosine uptake by
erythrocytes after blood sampling resulting in an artificial in-
crease in measured plasma adenosine concentration. The present
study does not rule out a small draflazine-induced increase in
plasma adenosine levels since intrasubject variability of the
adenosine detection method is relatively high, especially when
compared with detection methods of other endogenous com-
pounds like, for instance, (nor)epinephrine. Plasma adenosine
concentrations were measured up to 60 min after the start of
the draflazine infusion. Therefore, our data do not exclude a
detectable increase in plasma adenosine levels after this time
point or during more sustained nucleoside transport inhibition.
(b) The most likely explanation for adenosine receptor-
mediated hemodynamic and neurohumoral effects without any
change in plasma adenosine concentrations is that selective
adenosine transport inhibition results in accumulation of endog-
enous adenosine within the interstitium. As discussed in detail
elsewhere, the vascular endothelium may act as a strong barrier
against passage of metabolites (64-66). In normal tissue, the
nucleoside transporter bypasses this barrier but nucleoside trans-
port inhibition may transform the endothelium to a functional
barrier preventing adenosine to leave the interstitial space (66).
Interstitial adenosine may originate from ATP that is released
from sympathetic nerve endings (67) and subsequently dephos-
phorylated to adenosine by ecto-phosphatases and ecto-5 '-
nucleotidase located on the membranes of vascular smooth mus-
cle cells and endothelium. Since ATP is released from sympa-
thetic nerve endings by exocytosis, this source of adenosine is
not blocked by adenosine transport inhibition.
Ex vivo nucleoside transport inhibition in relation to
draflazine concentration and heart rate response. The relation
between blood drug concentration and ex vivo adenosine trans-
port inhibition could well be described by the Hill equation.
Since draflazine concentration was measured in whole blood,
this is not necessarily a reflection of draflazine concentration
at the level of the nucleoside transporter in the erythrocyte
membrane. Therefore, the accuracy and pharmacological impor-
tance of the Hill coefficient and the 50% inhibiting drug concen-
tration, as determined in this study, should not be overvalued.
Nevertheless, the high correlation between ex vivo nucleoside
transport inhibition and whole-blood draflazine concentration
provides an experimental base to use this functional parameter
as a tool to monitor draflazine treatment. This is further sup-
ported by the high correlation between ex vivo adenosine trans-
port inhibition and heart rate response. The relation between
heart rate response and ex vivo nucleoside transport inhibition
became steeper over time, reflecting a time delay between
draflazine-induced ex vivo nucleoside transport inhibition and
its effect on heart rate. Two processes may account for this
delay. First, intravenous infusion of draflazine rapidly inhibits
nucleoside transport at the erythrocyte membrane while diffu-
sion of draflazine into the interstitial space and inhibition of
adenosine transport in the vascular wall may take more time.
Second, it probably takes some time for endogenous adenosine
to accumulate and to reach concentrations that are sufficiently
high to evoke its full effect on heart rate.
Effect of0.5 mg draflazine onforearm vasodilator response
to adenosine. The forearm vasodilator response to adenosine
was significantly augmented by a draflazine dosage that did not
induce unwanted hemodynamic or neurohumoral side effects.
These results indicate that the cellular uptake of luminal adeno-
sine is inhibited, and that the increased adenosine concentrations
are available for stimulation of adenosine receptors that mediate
vascular relaxation. The reduced augmentation of adenosine-
mediated vasodilation at the three highest adenosine concentra-
tions, could be the result of the decreased nucleoside transport
inhibition at the time that the highest adenosine concentration
was infused. This is supported by the ex vivo nucleoside trans-
port inhibition which amounted to only 15% at the end if the
sixth adenosine infusion, compared with 22% at the. end of the
third adenosine infusion.
Limitations of the study and conclusions. Three limitations
of the study should be mentioned. First, the studies were per-
formed in healthy volunteers. We are not informed about the
influence of age and varying disease states on the systemic
effects of draflazine. Therefore, it cannot be excluded that in
the elderly or in patients with conditions like hypertension and
cardiovascular disease, a different dose-response pattern to
draflazine exists. Second, the hemodynamic and neurohumoral
responses to the adenosine transport inhibitor draflazine were
studied after a 24-h abstinence from caffeine-containing prod-
ucts. This abstinence period was included to prevent adenosine
antagonism by caffeine. In clinical practice, such a situation will
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almost never occur. Adenosine receptor upregulation during
caffeine use may have occurred and could have exaggerated the
effects of adenosine uptake inhibition after short-term absti-
nence from caffeine (68-70). Third, we studied the acute ef-
fects of short-term nucleoside transport inhibition. Our data do
not exclude the development of tolerance to increased levels of
endogenous adenosine that may arise during long-term nucleo-
side transport inhibition.
Before it can definitely be concluded that draflazine is a
feasible tool to potentiate the cardioprotective effects of adeno-
sine in humans, our findings should be confirmed in the coronary
vasculature. Furthermore, the present observation of in vivo
adenosine transport inhibition holds for intraarterially applied
adenosine and should be verified for interstitially formed adeno-
sine as during ischemia.
In conclusion, in healthy male volunteers, draflazine is able
to inhibit adenosine transport significantly both ex vivo as well
as in vivo. Heart rate appeared to be the most sensitive parame-
ter to detect systemic hemodynamic or neurohumoral effects.
When a draflazine dosage is injected that does not affect heart
rate, the forearm vasodilator response to adenosine is still po-
tentiated. Clinical trials are needed to investigate the possible
beneficial effect of adenosine uptake inhibition in the prevention
of ischemic injury. In these trials, caffeine intake should be
monitored, the optimal draflazine dosage can be determined
using heart rate as a marker of unwanted systemic effects, and
ex vivo adenosine transport inhibition can be used as a tool to
monitor efficacy and compliance.
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